Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance

DSpace/Manakin Repository

Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance

Citable link to this page

 

 
Title: Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance
Author: Kramer, Daniel B; Hatfield, Laura A; McGriff, Deepa; Ellis, Christopher R; Gura, Melanie T; Samuel, Michelle; Retel, Linda Kallinen; Hauser, Robert G

Note: Order does not necessarily reflect citation order of authors.

Citation: Kramer, Daniel B, Laura A Hatfield, Deepa McGriff, Christopher R Ellis, Melanie T Gura, Michelle Samuel, Linda Kallinen Retel, and Robert G Hauser. 2015. “Transvenous Implantable Cardioverter-Defibrillator Lead Reliability: Implications for Postmarket Surveillance.” Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease 4 (6): e001672. doi:10.1161/JAHA.114.001672. http://dx.doi.org/10.1161/JAHA.114.001672.
Full Text & Related Files:
Abstract: Background: As implantable cardioverter-defibrillator technology evolves, clinicians and patients need reliable performance data on current transvenous implantable cardioverter-defibrillator systems. In addition, real-world reliability data could inform postmarket surveillance strategies directed by regulators and manufacturers. Methods and Results: We evaluated Medtronic Sprint Quattro, Boston Scientific Endotak, and St Jude Medical Durata and Riata ST Optim leads implanted by participating center physicians between January 1, 2006 and September 1, 2012. Our analytic sample of 2653 patients (median age 65, male 73%) included 445 St Jude, 1819 Medtronic, and 389 Boston Scientific leads. After a median of 3.2 years, lead failure was 0.28% per year (95% CI, 0.19 to 0.43), with no statistically significant difference among manufacturers. Simulations based on these results suggest that detecting performance differences among generally safe leads would require nearly 10 000 patients or very long follow-up. Conclusions: Currently marketed implantable cardioverter-defibrillator leads rarely fail, which may be reassuring to clinicians advising patients about risks and benefits of transvenous implantable cardioverter-defibrillator systems. Regulators should consider the sample size implications when designing comparative effectiveness studies and evaluating new technology for preventing sudden cardiac death.
Published Version: doi:10.1161/JAHA.114.001672
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599526/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:23474039
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters